Analyst Consensus ?
ConsensusBuy12 ratings
Bullish12100.0%
Neutral00.0%
Bearish00.0%
BrightSpring Health Services, Inc. Common Stock · BTSG · FY2026 Q1 · Calendar Q2 2026
BrightSpring posts strong growth and raises 2026 guidance
BrightSpring’s reported growth, raised guidance, divestiture proceeds, and operating initiatives support a constructive earnings-period thesis, while leverage, integration, reimbursement, and margin durability remain the key tests.
Reported Before market openNASDAQHealthcare
$13.24B market cap
90quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.39
Consensus $0.29
EPS surprise
+34.5%
Reported versus consensus
Reported revenue
$3.61B
Consensus $3.39B
Revenue surprise
+6.6%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+9.6%
Event window
SPY move
+0.3%
Same window
Abnormal move
+9.3%
Stock minus SPY
Volume
4.5×
Versus trailing sessions
Subsequent drift
+14.1%
Up to 20 sessions
BTSGSPY benchmark
Ask FN2 about BTSG FY2026 Q1
Transcript, numbers and history already loaded
Why did BTSG rise 9.6% after beating EPS estimates in FY2026 Q1?What changed in BTSG's guidance and outlook in FY2026 Q1?Give me the bull and bear case for BTSG after FY2026 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The quarter showed 26% revenue growth and 45% adjusted EBITDA growth, alongside an $811 million Community Living divestiture and higher 2026 revenue and EBITDA guidance. Management also outlined continued infusion, specialty pharmacy, value-based care, and automation initiatives.
Guidance delta
Management raised 2026 guidance to $14.7–$15.2 billion of revenue and $795–$825 million of adjusted EBITDA.
Key takeaways
- Revenue increased 26% year over year to $3.6 billion, while adjusted EBITDA rose 45% to $190 million.
- Community Living divestiture generated $811 million of net cash proceeds before tax for debt repayment and balance-sheet strengthening.
- Management cited infusion growth, ultra-narrow LDD wins, generic utilization, fee-for-service hubs, and AI-enabled efficiencies as growth drivers.
- Amedisys and LHC integration is expected to contribute about $30 million of year-one EBITDA.
Management priorities
- Expand ultra-narrow LDDs and the Onco360 and CareMed portfolios.
- Scale acute and chronic specialty infusion, including concierge programs.
- Integrate Amedisys and LHC assets while pursuing disciplined tuck-in acquisitions.
- Advance AI and automation, value-based care contracts, and the lead ACO application.
Follow BTSG with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$66.89Current
$30Low
$63.86Average
$90High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 1, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BTIG | Buy | Buy | Maintain | Aug 13, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 14, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Jul 14, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 13, 2026 |
| UBS | Buy | Buy | Maintain | Jul 8, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 2, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jun 18, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Jun 8, 2026 |
| Mizuho | Outperform | Outperform | Maintain | May 5, 2026 |
| Stephens & Co. | Overweight | Overweight | Maintain | May 4, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | May 4, 2026 |
| Guggenheim | Buy | Buy | Maintain | Oct 1, 2024 |
Named analyst price targets
Upside is calculated against the persisted current price $66.89. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Deutsche Bank | Analyst unavailable | $70 | $60.82 | +4.6% | Aug 3, 2026 |
| Morgan Stanley | Analyst unavailable | $80 | $70 | +19.6% | Jul 14, 2026 |
| KeyBanc | Analyst unavailable | $80 | $69.64 | +19.6% | Jul 14, 2026 |
| Wells Fargo | Stephen Baxter | $78 | $71.43 | +16.6% | Jul 13, 2026 |
| Guggenheim | Analyst unavailable | $81 | $71.43 | +21.1% | Jul 13, 2026 |
| Raymond James | Parker Snure | $80 | $71.58 | +19.6% | Jul 9, 2026 |
| UBS | Analyst unavailable | $85 | $70.44 | +27.1% | Jul 8, 2026 |
| BTIG | David Larsen | $90 | $66.25 | +34.5% | Jun 22, 2026 |
| Cowen & Co. | Analyst unavailable | $81 | $64.43 | +21.1% | Jun 18, 2026 |
| Goldman Sachs | Scott Fidel | $71 | $57.4 | +6.1% | Jun 8, 2026 |
| Morgan Stanley | Erin Wright | $71 | $59.98 | +6.1% | Jun 2, 2026 |
| BMO Capital | Analyst unavailable | $70 | $59.16 | +4.6% | May 21, 2026 |
| Morgan Stanley | Analyst unavailable | $62 | $52.44 | -7.3% | May 6, 2026 |
| Deutsche Bank | Analyst unavailable | $60 | $53.51 | -10.3% | May 4, 2026 |
| BTIG | Analyst unavailable | $65 | $52.58 | -2.8% | May 4, 2026 |
| Stephens | Analyst unavailable | $64 | $52.58 | -4.3% | May 4, 2026 |
| KeyBanc | Analyst unavailable | $60 | $52.58 | -10.3% | May 4, 2026 |
| Wells Fargo | Stephen Baxter | $61 | $52.58 | -8.8% | May 4, 2026 |
| BMO Capital | Analyst unavailable | $60 | $52.58 | -10.3% | May 1, 2026 |
| Leerink Partners | Whit Mayo | $49 | $43.82 | -26.7% | Mar 18, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $49 | $40.65 | -26.7% | Mar 2, 2026 |
| BTIG | David Larsen | $55 | $39.27 | -17.8% | Feb 2, 2026 |
| BMO Capital | Analyst unavailable | $46 | $39.6 | -31.2% | Jan 23, 2026 |
| Mizuho Securities | Ann Hynes | $45 | $39.1 | -32.7% | Jan 9, 2026 |
| Wells Fargo | Analyst unavailable | $43 | $40.67 | -35.7% | Jan 7, 2026 |
| BTIG | Analyst unavailable | $50 | $38 | -25.3% | Dec 23, 2025 |
| Mizuho Securities | Analyst unavailable | $42 | $35.58 | -37.2% | Dec 18, 2025 |
| KeyBanc | Matthew Gillmor | $45 | $35.89 | -32.7% | Dec 12, 2025 |
| Stephens | Analyst unavailable | $44 | $35.23 | -34.2% | Dec 10, 2025 |
| Wells Fargo | Stephen Baxter | $39 | $33.91 | -41.7% | Nov 12, 2025 |
| Mizuho Securities | Ann Hynes | $38 | $34.47 | -43.2% | Oct 29, 2025 |
| BTIG | David Larsen | $41 | $34 | -38.7% | Oct 29, 2025 |
| UBS | Analyst unavailable | $42 | $34.44 | -37.2% | Oct 29, 2025 |
| Jefferies | Brian Tanquilut | $36 | $31.89 | -46.2% | Oct 21, 2025 |
| Mizuho Securities | Analyst unavailable | $32 | $29.45 | -52.2% | Oct 17, 2025 |
| Morgan Stanley | Analyst unavailable | $32 | $28.85 | -52.2% | Oct 14, 2025 |
| Wells Fargo | Stephen Baxter | $33 | $28.87 | -50.7% | Oct 7, 2025 |
| Deutsche Bank | Pito Chickering | $30 | $25.48 | -55.2% | Sep 8, 2025 |
| Mizuho Securities | Ann Hynes | $26 | $21.82 | -61.1% | May 5, 2025 |
Track every rating change on BTSG the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationBrightSpring Health Services, Inc. operates across the United States, offering a range of healthcare solutions directly within patients' homes and local communities. The company's extensive platform focuses on providing crucial pharmacy and medical provider services, including both clinical care and supportive assistance, to individuals covered by Medicare, Medicaid, and private insurance. Patients receive care from a dedicated team of clinical professionals and licensed pharmacists. Formerly known as Phoenix Parent Holdings Inc., the company officially adopted the name BrightSpring Health Services, Inc. in May 2021. Founded in 1974, its headquarters are located in Louisville, Kentucky.
Historical context
All BTSG earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +10.0% | BrightSpring posts strong Q3 growth as pharmacy leads |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
| BBIO BridgeBio Pharma, Inc. | FY2026 Q3 · Calendar Q4 2026 | +22.5% | +6.0% | BridgeBio advances three launches while Attruby momentum holds |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the BTSG recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-01T18:20:42.277897+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-01T18:20:42.275035+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-01. For educational purposes only; not investment advice.